TIP Protocol for Germ Cell Tumors
The TIP regimen consists of paclitaxel 250 mg/m² on day 1, ifosfamide 1.5 g/m² on days 2-5, and cisplatin 25 mg/m² on days 2-5, repeated every 3 weeks for 4 cycles, and is primarily used as conventional-dose salvage chemotherapy for relapsed or refractory germ cell tumors. 1
Protocol Specifications
The standard TIP dosing from ESMO guidelines is:
- Paclitaxel: 250 mg/m² IV on Day 1
- Cisplatin: 25 mg/m² IV on Days 2-5
- Ifosfamide: 1.5 g/m² IV on Days 2-5
- Cycle frequency: Every 3 weeks
- Number of cycles: 4 cycles typically 1
Critical supportive care: All patients require mesna for hemorrhagic cystitis prophylaxis with ifosfamide 2, and standard paclitaxel premedication (dexamethasone 20 mg PO 12 and 6 hours before, diphenhydramine 50 mg IV 30-60 minutes before, and H2-blocker 30-60 minutes before paclitaxel) 3.
Clinical Indications
Primary Use: Salvage Therapy
TIP is established as a conventional-dose salvage regimen for patients who relapse after first-line cisplatin-based chemotherapy. 1 The 2013 ESMO guidelines explicitly state "four cycles TIP, typically as conventional dose salvage chemotherapy" 1.
For salvage treatment, TIP is one of several acceptable cisplatin-based regimens with similar efficacy, including VIP (etoposide/ifosfamide/cisplatin) and VeIP (vinblastine/ifosfamide/cisplatin) 1, 4. No conventional-dose salvage regimen has shown unequivocal superiority over another 4.
Efficacy in Salvage Setting
The landmark phase II trial demonstrated that among 30 carefully selected patients with favorable prognostic features (testis primary, prior complete response to first-line therapy), TIP achieved:
- 80% favorable response rate (complete response or partial response with negative markers)
- 73% durable complete responses at median 33 months follow-up 5
More recent long-term data with 104 patients and median 8.9 years follow-up showed:
- 5-year progression-free survival: 66%
- 5-year overall survival: 69%
- Among favorable-risk patients: 67% PFS and 72% OS at 5 years
- Even among unfavorable-risk patients: 59% PFS and 56% OS at 5 years 6
Patient Selection Considerations
The original TIP studies specifically selected patients with favorable prognostic features - testis primary tumor site and prior complete response to first-line chemotherapy 5. However, subsequent real-world experience demonstrates efficacy even in patients with unfavorable risk factors 6.
According to the International Prognostic Factor Study Group (IPFSG) classification for relapsed disease, prognostic factors include: primary tumor site, response to first-line treatment, progression-free interval, AFP and hCG levels at salvage, and presence of liver/bone/brain metastases 1.
Alternative Dosing Considerations
A lower paclitaxel dose of 175 mg/m² has been studied but showed inferior efficacy - achieving only 65% favorable response rate and 47% 2-year disease-free survival 7. This reinforces that the full 250 mg/m² paclitaxel dose is necessary for optimal outcomes.
First-Line Use: Not Recommended
TIP should NOT be used as first-line therapy for metastatic germ cell tumors. A phase II trial specifically tested TIP as first-line treatment in poor-prognosis patients with unfavorable serum tumor marker decline after the first cycle of chemotherapy. The study was terminated early after achieving only 21% complete response rate among the first 19 patients, failing to meet efficacy endpoints 8. Four cycles of BEP (bleomycin/etoposide/cisplatin) remains the standard first-line treatment for intermediate and poor-prognosis disease 1.
Toxicity Profile
Myelosuppression is the major toxicity, with granulocytopenia grade 3-4 occurring in approximately 8% of courses and febrile neutropenia in 7% 7. G-CSF support is typically required 5.
Peripheral neurotoxicity is significant: sensorimotor impairment grade 2-4 occurs in 29% of patients, with paresthesias grade 2-4 in 24% 9. This is notably higher than with non-paclitaxel containing regimens and represents a key disadvantage of this salvage strategy.
Other toxicities include skin reactions (grade 2-3 in 15%) 9 and the expected nephrotoxicity from cisplatin, though this can be mitigated by substituting nedaplatin in patients with pre-existing renal dysfunction 10.
Common Pitfalls
- Do not use reduced paclitaxel doses - the 250 mg/m² dose is necessary for efficacy 7
- Do not use TIP as first-line therapy - it has not shown superiority to standard BEP and failed in a phase II trial 8
- Ensure proper patient selection - TIP works best in patients with favorable prognostic features for salvage therapy
- Monitor for cumulative neurotoxicity - approximately one-third of patients develop significant peripheral neuropathy 9
- Always use mesna with ifosfamide to prevent hemorrhagic cystitis 2
Ongoing Research
The randomized TIGER trial (NCT02375204) is comparing TIP with high-dose chemotherapy to determine the optimal second-line treatment approach 6. Until these results are available, TIP remains a standard conventional-dose salvage option alongside VIP and VeIP, with choice between regimens based on individual patient factors and institutional experience.